Patents by Inventor Harry G. Brittain

Harry G. Brittain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic forms of naltrexone
    Patent number: 8975272
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 10, 2015
    Assignee: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • ADJUVANT TO THROMBOLYTIC THERAPY FOR THE TREATMENT OF FROSTBITE
    Publication number: 20140343021
    Abstract: A method of treating frostbite in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic Forms of Naltrexone
    Publication number: 20140303200
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: April 10, 2014
    Publication date: October 9, 2014
    Applicant: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20140296189
    Abstract: A method of reducing niacin flushing in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Application
    Filed: May 21, 2014
    Publication date: October 2, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20140288029
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Application
    Filed: June 4, 2014
    Publication date: September 25, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20140235594
    Abstract: A method of treating a condition associated with excess gluatame in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20140179644
    Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Application
    Filed: February 25, 2014
    Publication date: June 26, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • COMPOSITIONS AND METHODS FOR TRANSMUCOSAL ABSORPTION
    Publication number: 20140171515
    Abstract: The invention provides compositions and methods for administering compounds for transmucosal absorption. The compositions and methods have a number of surprising pharmacokinetic benefits over oral administration of a compound.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 19, 2014
    Inventors: Seth Lederman, Giorgio Reiner, Harry G. Brittain
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20140148418
    Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 8735420
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 27, 2014
    Assignee: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 8685948
    Abstract: A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: April 1, 2014
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip Felice
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20130345183
    Abstract: A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 26, 2013
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic Forms of Naltrexone
    Publication number: 20130253199
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: November 30, 2012
    Publication date: September 26, 2013
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 8389540
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: March 5, 2013
    Assignee: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20130012482
    Abstract: A water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 8304404
    Abstract: An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: November 6, 2012
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Intravenous Formulation with Water-Soluble CoCrystals of Acetylsalicylic Acid and Theanine
    Publication number: 20120190655
    Abstract: An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture.
    Type: Application
    Filed: April 5, 2012
    Publication date: July 26, 2012
    Applicant: Theraprin Pharmaceuticals, Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 8173625
    Abstract: A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 8, 2012
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE
    Publication number: 20100286099
    Abstract: A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.
    Type: Application
    Filed: May 8, 2009
    Publication date: November 11, 2010
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic Forms of Naltrexone
    Publication number: 20080227804
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: September 25, 2007
    Publication date: September 18, 2008
    Applicant: ALKERMES, INC.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright